在膀癌中,SLC7A5与恶性瘤和免疫治疗反应相关
Chunyu Zhang1, Yanan Wang1, Xiangdong Guo1
1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer cell international
|May 24, 2024
概括
溶性载体家族7成员5 (SLC7A5) 促进膀癌的进展,并与炎症性瘤微环境有关. 向SLC7A5可能会提高膀癌患者的免疫疗法和放射疗法的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 代谢重编程对于膀癌的发展至关重要.
- 溶性载体家族7成员5 (SLC7A5) 在膀癌中的作用需要进一步阐明.
研究的目的:
- 为了研究SLC7A5表达和膀癌之间的相关性.
- 探索SLC7A5对瘤微环境和治疗反应的影响.
主要方法:
- 生物信息学分析,西部抹杀,细胞循环,增殖和入侵试验被采用.
- 分析了免疫特征,包括免疫周期,调节器,检查点和透细胞.
- 全癌症分析评估了SLC7A5表达模式和各种癌症中的免疫作用.
主要成果:
- 高SLC7A5表达与预后不佳,Wnt通路激活和膀癌细胞增强的增殖,迁移和入侵有关.
- SLC7A5与炎症性瘤微环境,增加免疫细胞透和T细胞炎症有关.
- 高SLC7A5的患者从EGFR向治疗,免疫治疗和放射治疗中受益,而低SLC7A5的患者对向治疗和抗血管生成治疗有反应.
结论:
- 在膀癌中,SLC7A5表达可以预测免疫治疗,放射治疗和化疗的治疗反应.
- 结合针对SLC7A5和免疫治疗,为膀癌提供了一个有前途的治疗策略.
相关概念视频
01:27Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K